Compare Gilead Sciences, Inc. (GILD) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Marqeta Inc — how do they compare? Gilead Sciences, Inc. trades at $132.93 (market cap $163.51B), while Marqeta Inc trades at $17.62 (market cap $1.83B). The key difference: Gilead Sciences, Inc. is far larger — about 89.3× Marqeta Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| GILD | MQ | |
|---|---|---|
Market Cap | $163.51B | $1.83B |
Sector | Health | Technology |
52-Week High | $155.80 | $27.32 |
52-Week Low | $108.22 | $15.04 |
Enterprise Value | $178.05B | $1.13B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
MQ trades at $16.13, down 1.83% on the day, with a bullish technical signal from moving averages and oversold RSI. The company reported a Q1 2026 EPS beat of $0.08 versus -$0.0136 expected, though full-year 2025 revenue grew to $624.88M while net income was -$13.93M. A 4:1 reverse stock split took effect July 1, 2026, and expansion into 30 European markets via Banking Circle was announced May 26, 2026.
MQ's outlook is mixed: analyst consensus is a $19.00 price target with 32% buy ratings, but high valuation ratios (P/E 434.25) and thin net margins (0.33%) pose risks. Positive cash flow trends and credit market expansion offer growth potential, yet shareholder litigation and volatile earnings history require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
